Objective:To investigate the anticancer effects of Xi Huang Capsule(XH)in vivo,thirty-two Nu/Nu mice inoculated with human breast cancer SKBR-3 cells and twenty-four Nu/Nu mice inoculated with murine breast cancer 4T1...Objective:To investigate the anticancer effects of Xi Huang Capsule(XH)in vivo,thirty-two Nu/Nu mice inoculated with human breast cancer SKBR-3 cells and twenty-four Nu/Nu mice inoculated with murine breast cancer 4T1 cells were randomized into the control group,XH group,5-FU group and combination of XH and 5-FU group in a 1:1:1:1 ratio.Method:The 5-FU group was injected with 5-FU at 30 mg/kg intraperitoneally every third day;XH group received doses of 0.25g/kg of XH by gastric perfusion each day;The control group was injected daily with normal saline(N.S.)intraperitoneally and the combination group was treated with 5-FU and XH on the same schedules as above.All treatments lasted for 15 days in human SKBR-3 breast cancer cells and 11 days in mice breast cancer 4T1 cells.Tumor volume,tumor weight,organ index,and change in body weight of nude mice were measured,respectively.PCNA and vimentin protein expression were examined by immunohistochemical assay.Results:In SKBR-3 cell xenograft tumor experiments,the XH group,5-FU group and the combination group had significantly smaller tumor volumes(966.39±80.23mm3,892.21±150.77mm3,817.93±162.47 mm3,respectively),and lower tumor weights(0.90±0.14g,0.84±0.32,0.86±0.24g,respectively),as compared with the control group(all P<0.05).The combination group had the highest tumor inhibition rate(38.7%).The similar results emerged in 4T1 cell xenograft tumor.Only the combination group had the least body weight increase of SKBR-3 cells xenograft tumor(P<0.05 as compared with the control group).In SKBR-3 cell xenograft tumor experiments,the 5-FU group had a lower Liver index(43.02±5.00mg/g versus 50.95±4.59mg/g)as compared with the control group(P<0.05),whereas the combination group reversed the changes in the 5-FU group with Liver index of 49.69±4.81 mg/g(P<0.05).The combination group had a higher Spleen index(5.95±1.62 versus 4.72±0.66mg/g)as compared with the control group,and had a higher Spleen index as compared with the 5-FU group(4.54±0.79 mg/g,P<0.05).In 4T1 cell xenograft tumor experiments,the 5-FU group and the combination group had a lower Liver index(47.69±6.41,49.87±5.96 versus 58.95±7.33),but Liver index of XH group had no significantly difference as compared with the control group.The Spleen index was the same to that in SKBR-3 cells xenograft tumor.PCNA and vimentin expression of XH group was significantly lower than that of the control group.Conclusion:The treatment of XH was equally effective in the inhibition of tumor growth,and may have potentially additional benefit in improving the general condition and immunity of the mice not only in human breast cancer cell but also in rat mammary carcinoma in vivo.展开更多
文摘Objective:To investigate the anticancer effects of Xi Huang Capsule(XH)in vivo,thirty-two Nu/Nu mice inoculated with human breast cancer SKBR-3 cells and twenty-four Nu/Nu mice inoculated with murine breast cancer 4T1 cells were randomized into the control group,XH group,5-FU group and combination of XH and 5-FU group in a 1:1:1:1 ratio.Method:The 5-FU group was injected with 5-FU at 30 mg/kg intraperitoneally every third day;XH group received doses of 0.25g/kg of XH by gastric perfusion each day;The control group was injected daily with normal saline(N.S.)intraperitoneally and the combination group was treated with 5-FU and XH on the same schedules as above.All treatments lasted for 15 days in human SKBR-3 breast cancer cells and 11 days in mice breast cancer 4T1 cells.Tumor volume,tumor weight,organ index,and change in body weight of nude mice were measured,respectively.PCNA and vimentin protein expression were examined by immunohistochemical assay.Results:In SKBR-3 cell xenograft tumor experiments,the XH group,5-FU group and the combination group had significantly smaller tumor volumes(966.39±80.23mm3,892.21±150.77mm3,817.93±162.47 mm3,respectively),and lower tumor weights(0.90±0.14g,0.84±0.32,0.86±0.24g,respectively),as compared with the control group(all P<0.05).The combination group had the highest tumor inhibition rate(38.7%).The similar results emerged in 4T1 cell xenograft tumor.Only the combination group had the least body weight increase of SKBR-3 cells xenograft tumor(P<0.05 as compared with the control group).In SKBR-3 cell xenograft tumor experiments,the 5-FU group had a lower Liver index(43.02±5.00mg/g versus 50.95±4.59mg/g)as compared with the control group(P<0.05),whereas the combination group reversed the changes in the 5-FU group with Liver index of 49.69±4.81 mg/g(P<0.05).The combination group had a higher Spleen index(5.95±1.62 versus 4.72±0.66mg/g)as compared with the control group,and had a higher Spleen index as compared with the 5-FU group(4.54±0.79 mg/g,P<0.05).In 4T1 cell xenograft tumor experiments,the 5-FU group and the combination group had a lower Liver index(47.69±6.41,49.87±5.96 versus 58.95±7.33),but Liver index of XH group had no significantly difference as compared with the control group.The Spleen index was the same to that in SKBR-3 cells xenograft tumor.PCNA and vimentin expression of XH group was significantly lower than that of the control group.Conclusion:The treatment of XH was equally effective in the inhibition of tumor growth,and may have potentially additional benefit in improving the general condition and immunity of the mice not only in human breast cancer cell but also in rat mammary carcinoma in vivo.
